sglt2 inhibitors vs glp-1 agonists Common systemic effects of either or GLP-1R APhA 2025: GLP-1 Receptor Agonists

We treat it like medicine, which means saying no when the patient isnt ready, monitoring closely when they are, and adjusting protocols based on what bloodwork shows rather than what the patient wants to hear

So a drug company wouldnt be too keen on a trial like that unless they were sure their drug was either better or at least as good as

About 1 in 8 adult Americans has already used GLP-1 drugs

Two collagen types dominate: Type I collagen (mature tendon structure) Type III collagen (early repair phase) In rodent studies, BPC-157-treated tendons showed: Increased type I collagen deposition Improved fiber parallel alignment Better biomechanical strength This suggests influence over: TGF- signalling Matrix metalloproteinases (MMPs) Extracellular matrix remodelling enzymes Balanced ECM remodelling prevents disorganized scar tissue

GHK is intended strictly for in vitro research applications